^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IO-108
i
Other names: IO-108, LILRB2 Antibody
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Immune-Onc Therap
Drug class:
ILT-4 inhibitor
Related drugs:
5ms
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=91, Completed, Immune-Onc Therapeutics | Active, not recruiting --> Completed | N=309 --> 91
Trial completion • Enrollment change • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • IO-108
6ms
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors (clinicaltrials.gov)
P1, N=38, Completed, Immune-Onc Therapeutics | Recruiting --> Completed | N=89 --> 38
Trial completion • Enrollment change
|
Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • IO-108
8ms
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=309, Active, not recruiting, Immune-Onc Therapeutics | Phase classification: P1b --> P1 | Trial completion date: Dec 2024 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • IO-108
1year
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1b, N=309, Active, not recruiting, Immune-Onc Therapeutics | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • IO-108
over1year
Novel Myeloid Checkpoint Inhibitors Targeting the LILRB (ILT) Family Members (PEGS 2023)
These include IO-108, an antagonist antibody targeting LILRB2 (ILT4), in Phase I clinical development for solid tumors and IO-202; an antagonist antibody targeting LILRB4 (ILT3), in Phase I clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106, a first-in-class antagonist antibody targeting LAIR1; IO-312, a novel bispecific antibody targeting LILRB4 and CD3 (LILRB4 x CD3); and multiple undisclosed programs.
Checkpoint inhibition
|
LILRB4 (Leukocyte Immunoglobulin Like Receptor B4) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
|
IO-202 • IO-106 • IO-108 • IO-312
over2years
IO-108, A fully human therapeutic antibody blocking the myeloid checkpoint LILRB2/ILT4, promotes innate and adaptive anti-cancer immunity in preclinical studies (AACR 2022)
Importantly, IO-108 presents a favorable pharmacokinetic and safety profile in preclinical models. Collectively, the preclinical characterization of IO-108 enabled a comprehensive clinical biomarker plan and lends rationale to the clinical study (NCT05054348) of IO-108 as a novel immunotherapy for multiple solid tumor types, including those relapsed/refractory to standard of care therapies.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD4 (CD4 Molecule) • STING (stimulator of interferon response cGAMP interactor 1)
|
IO-108
Share via
